PIGR predicts good clinical outcomes and plays a tumor suppressor role in the development of breast cancer
PIGR can suppress breast cancer cell growth <i>in vitro</i> and <i>in vivo</i> and is an independent protective factor for BRCA patients' prognosis. PIGR correlates with tumor immunity and exerts anti-tumor effects in BRCA. PIGR might be a novel prognostic biomarker and therapeutic target.
Authors
- Ke Dong (ORCID: https://orcid.org/0000-0002-5734-2373)
- Haidong Gao (ORCID: https://orcid.org/0000-0001-5560-6323)
- Zhi Sun (ORCID: https://orcid.org/0000-0001-6007-4923)
- Peng Li (ORCID: https://orcid.org/0000-0002-9026-9999)
- Guang‐Hui Zhao (ORCID: https://orcid.org/0000-0002-3511-6332)
- Tengfei Jiang (ORCID: https://orcid.org/0000-0002-4069-7223)
- Qian Pu (ORCID: https://orcid.org/0000-0001-8527-1026)
- Yanrong Lv (ORCID: https://orcid.org/0000-0001-6862-6788)
Institutions
- Qingdao University (CN)
- Shandong University (CN)
- Qilu Hospital of Shandong University (CN)
- Qingdao Women and Children's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.3389/fonc.2025.1439120
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18